Navigation Links
Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
Date:7/7/2008

V."

Steve Worland, Ph.D., Anadys' President and CEO, commented, "The decision to take ANA773 into HCV, which will be our third clinical development program to commence dosing this year, reflects an expansion of Anadys' development efforts in HCV. As an approach to treat hepatitis C, the TLR7 mechanism is independent from, and potentially complementary to, ANA598, Anadys' non-nucleoside HCV polymerase inhibitor currently in Phase I clinical development." Commenting on the expected impact this expansion will have on the Company's cash outlook for 2008, Dr. Worland added, "Because the ANA773 hepatitis C program is highly leveraged off our oncology program, we expect to carry forward all three clinical development programs this year within our previous 2008 cash utilization projection of $29 to $31 million."

ANA773 Phase I Clinical Trial in HCV

The Phase I clinical trial of ANA773 in HCV will be conducted under a two-part protocol. Part A of the study will include both single and multiple doses of ANA773 in healthy volunteers. Successive cohorts of volunteers will receive ascending dose levels of ANA773. The primary objectives of Part A of the study are to assess safety and tolerability. In Part B of the study, HCV patients will receive ANA773 every other day for 28 days. The primary objectives of Part B are to assess safety, tolerability and viral load decline. The starting dose level in HCV patients will be selected based on safety, tolerability and immune responses seen in healthy volunteers in Part A. It is expected that this study design will allow initial dosing in HCV patients at a dose that will have demonstrated a desired magnitude of immune stimulation in the healthy subjects, and that dosing in patients will initiate prior to completion of dose escalation in Part A of the study. Approximately 40 healthy volunteers and 24 patients are anticipated to be enrolled in this study. Dosing is expected to begin in healthy volunteers within the nex
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
2. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
3. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
6. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
7. Isis Pharmaceuticals Conference Call Notice
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
10. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
11. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... Dec. 11, 2014 Research and Markets ... of the "Drug Injection Devices to 2020" ... http://photos.prnewswire.com/prnh/20130307/600769 As new ... expanding list of health conditions, drug developers have ... the administration process and increase the efficiency and ...
(Date:12/13/2014)... Dec. 12, 2014  Radiologists can transmit their ... to their referring physicians, electronic health records (EHR) ... selected technology.  That was the ... Corporation (ADS) at the recent Radiology Society of ... of radiology reports in this manner also helps ...
(Date:12/13/2014)... Dec 12, 2014 Mindray Medical International Limited ... manufacturer and marketer of medical devices worldwide, today announced ... shareholders held in Hong Kong ... Mindray shareholders voted to re-elect incumbent directors Li Xiting ... Mindray,s shareholders did not re-elect Peter Wan ...
Breaking Medicine Technology:Drug Injection Devices to 2020 2Drug Injection Devices to 2020 3Drug Injection Devices to 2020 4Advanced Data Systems Presents on Interface-Free EHR Communications at RSNA's 2014 Conference: Streamlining Communication of Reports and Images to Referring Physicians 2Advanced Data Systems Presents on Interface-Free EHR Communications at RSNA's 2014 Conference: Streamlining Communication of Reports and Images to Referring Physicians 3Mindray Announced Shareholder Resolutions Post 2014 Annual General Meeting 2
... June 30, 2011 Endo Pharmaceuticals (Nasdaq: ENDP ... comparing the novel investigational drug axomadol against placebo in the ... pain. The results indicate that axomadol did not meet predetermined ... of the data and evaluating the path forward for the ...
... YORK, June 30, 2011 Reportlinker.com announces that ... its catalogue: Medical Devices & ... http://www.reportlinker.com/p0565215/Medical-Devices--Diagnostics-Equipments-in-India.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnostics By 2014, the Indian ... reach US$ 6.41 million, growing 15.5% annually. ...
Cached Medicine Technology:Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain 2Medical Devices & Diagnostics Equipments in India 2Medical Devices & Diagnostics Equipments in India 3Medical Devices & Diagnostics Equipments in India 4Medical Devices & Diagnostics Equipments in India 5
(Date:12/17/2014)... Project Veritas is releasing a video interview ... economist and Obamacare architect Jonathan Gruber to public attention. ... interview, which is being distributed on YouTube. , During ... in the Affordable Care Act in order to hide ... dollar per year tax grab. , “President Obama promised ...
(Date:12/17/2014)... parents should leave prenatal picture-taking to medical professionals, the ... ultrasound imaging and heartbeat monitors to get "keepsake" images ... "Although there is a lack of evidence ... monitors, prudent use of these devices by trained health ... engineer, said in an agency news release. "Ultrasound ...
(Date:12/17/2014)... Alan Mozes HealthDay Reporter ... the holiday party season fast approaching, a new study reveals ... DUI arrests have fewer drunk drivers on their roads. ... more vigilantly are better able to deter inebriated revelers from ... any new laws are being passed regarding drinking and driving," ...
(Date:12/15/2014)... 15, 2014 A recent survey found ... women as impacting skin health and beauty were: “Connections,” ... skin care.” Water and health advocate and radio host ... article describing the survey and the Four C’s.* Kleyne ... every category discussed would benefit from paying attention to ...
(Date:12/15/2014)... 15, 2014 Main Street Dental Team ... weighing in on a new study providing evidence on ... oral hygiene of children. , Sufficient enough evidence already ... as pop or juice drinks, with the onset of ... is whether drinks listed as 100% fruit juice, meaning ...
Breaking Medicine News(10 mins):Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 2Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2
... Mass., July 29 - Boston Scientific Corporation (NYSE: BSX ... Katharine T. Bartlett and Bruce L. Byrnes as Directors. ... Pye Professor of Law at the Duke University School of Law, ... through a period of major strategic expansion. During Bartlett,s tenure ...
... , NEW ORLEANS, July 29 ... its pioneering spirit again by leading the way to making healthy alternatives ... , , Consumers in Tokyo will be the first ... the first store planned to open in 2010. Japan makes sense as ...
... BATESVILLE, Ind., July 29 Hillenbrand, Inc. (NYSE: HI ... Wednesday, Aug. 12, 2009. The full text of the release and ... www.HillenbrandInc.com . , , The company ... financial analysts the same day at 8 a.m. ET. During the ...
... EMERYVILLE, Calif., July 29 Bionovo, Inc. (Nasdaq: BNVI ... needs in women,s health and oncology, today announced that Dr. Mary ... President and CFO, will be presenting at the BMO Capital Markets ... Wednesday, August 5, 2009. The event will be held at the ...
... , SOUTH SAN FRANCISCO, Calif., July 29 ... biopharmaceutical company focused on innovative oncology therapies, today announced that ... to provide a corporate overview, including a discussion about the ... at two upcoming investor conferences: , , ...
... half in study of Finnish men , WEDNESDAY, July 29 ... high-intensity exercise appears to reduce the risk of cancer, a ... men, aged 42 to 61, whose leisure-time physical activity was ... history of cancer, according to the report published online July ...
Cached Medicine News:Health News:Boston Scientific Announces Election of Katharine Bartlett and Bruce Byrnes to Its Board of Directors 2Health News:Boston Scientific Announces Election of Katharine Bartlett and Bruce Byrnes to Its Board of Directors 3Health News:Smoothie King Expansion Signals International Trend Toward Healthy Living 2Health News:Smoothie King Expansion Signals International Trend Toward Healthy Living 3Health News:Hillenbrand Announces Third-Quarter Earnings Release Date and Conference Call 2Health News:Bionovo to Present at the BMO Capital Markets Ninth Annual Focus on Healthcare Conference 2Health News:Poniard Pharmaceuticals to Present at Two Upcoming Investor Conferences in August 2
Titanium. Straight shafts with 6.5 mm tying platform. Round knurled handle with dull finish. Overall length 4.4 inches....
Angled shafts with 4 mm tying patform. Serrated handle with dull finish. Most popular size or model. Overall length 3.2 inches....
Angled 45 degree shafts 8 mm from tip to bend with 4 mm tying platform. Smooth handle with dull finish. Overall length 3.2 inches....
Curved shafts and tips with 6 mm tying platform. Wide serrated handle with dull finish. Overall length 4.3 inches....
Medicine Products: